CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
PreMeDosE develops a new assay to measure cytochrome P450 enzyme activity, enabling personalized drug dosing by assessing both genetic and external factors affecting drug elimination. This technology aims to reduce adverse drug reactions and improve patient outcomes in healthcare settings.
PreMeDosE aims to ascertain the technical and commercial viability of a novel cytochrome P450 (CYP) enzyme activity assay, to enable truly personalised drug dosing for the first time.
The CYP enzymes are responsible for the elimination of the majority of therapeutic drugs from the body.
However, inter-individual variation in CYP activity leads to personal differences in drug elimination kinetics, both toxic accumulation (too slow elimination) and loss of therapeutic efficacy (too rapid eliminati…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
